Lithium carbonate in amyotrophic lateral sclerosis: lack of efficacy in a dose-finding trial
- Chiò, A
- Borghero, G
- Calvo, A
- Capasso, M
- Caponnetto, C
- Corbo, M
- Giannini, F
- Logroscino, G
- Mandrioli, J
- Marcello, N
- Mazzini, L
- Moglia, C
- Monsurrò, Mr
- Mora, G
- Patti, F
- Pietrini, V
- Pisano, F
- Pupillo, E
- Sabatelli, Mario (ORCID:0000-0001-6635-4985)
- Salvi, F
- Silani, V
- Simone, Il
- Sorarù, G
- Tola, Mr
- Volanti, P
- Beghi, E
- Perini, M.
Publication date
January 2010
DOI Publisher
Ovid Technologies (Wolters Kluwer Health) ISSN
0028-3878Abstract
A neuroprotective effect of lithium in amyotrophic lateral sclerosis (ALS) has been recently reported. We performed a multicenter trial with lithium carbonate to assess its tolerability, safety, and efficacy in patients with ALS, comparing 2 different target blood levels (0.4-0.8 mEq/L, therapeutic group [TG], vs 0.2-0.4 mEq/L, subtherapeutic group [STG])
Add to ORKG